End point Valsartan Valsartan+HCTZ p

Slides:

Advertisements

Similar presentations

The DRASTIC Trial. Dutch Renal Artery Stenosis Intervention Cooperative Reference van Jaarsveld BC, Krijnen P, Derkx FHM, et al. Resistance to antihypertensive.

Advertisements

Valsartan Antihypertensive Long-Term Use Evaluation Results

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

Cholesterol quintile (mg/dL)

NHANES III Prevalence of Hypertension* According to BMI

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.

William B. Kannel, MD, FACC Former Director, Framingham Heart Study

Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

UK Renal Registry 9 th Annual Report 2006 Fig 10.1 Systolic BP mm Hg (pre-HD)

Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.

לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.

A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

A Controlled Trial of Renal Denervation for Resistant Hypertension

CSM-1 Patients With and Without Obesity LSM Difference and 95% CI in BP (230, 231 Pooled) † Diastolic BP Overall (N = 1,191) Obese.

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.

Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.

Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.

Predictive value of CRP vs LDL-C (i) Ridker PM, et al. N Engl J Med 2002;347: Quintile of CRP (mg/L)

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and Efficacy of Low Blood Pressures Among.

Study design: a randomized placebo- controlled crossover trial of 2 periods of 4 weeks Nicole A.J. van der Linde, et al. Hypertension 2006;47;

Copyright © 2010 American Medical Association. All rights reserved.

Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI Clinical Therapeutics

Aaron P Kithcart Giuseppe Curigliano Joshua A. Beckman Cardio-Oncology

Flowchart of participants

Aliskiren and Valsartan for Antihypertensive Therapy Trial

Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.

Copyright © 2007 American Medical Association. All rights reserved.

Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus by Francesca Viazzi, Pamela Piscitelli, Antonio.

Circ Cardiovasc Qual Outcomes

by Katie Ayers, Loretta M. Byrne, Anthony DeMatteo, and Nancy J. Brown

Oana Dickinson et al. JACEP 2016;2:

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Mean BP from initial visit to four years

Hypertension Guidelines

Early Systolic Blood Pressure Changes in Incident Hemodialysis Patients Are Associated with Mortality in the First Year Kidney Blood Press Res 2012;35:663–670.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

Why double blind, controlled randomized trials?

Time point Difference in systolic BP (mm Hg) p

End point Net change with soy supplements vs control (95% CI) p

Chapter 28 Nutrition, Lifestyle, and Hypertension

Level of risk factor control in the overall sample and by gender

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Life expectancy and baseline BP: Male participants

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

Volume 377, Issue 9771, Pages (March 2011)

William T. Abraham et al. JCHF 2015;3:

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Flow chart of the 1683 study members at age 60–64 years by hypertension (HT) status. Flow chart of the 1683 study members at age 60–64 years by hypertension.

Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.

Baseline Characteristics by hs-CRP

RECORD Study: Enrollment and Outcomes

Volume 71, Issue 9, Pages (May 2007)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Volume 75, Issue 1, Pages (January 2009)

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Atrasentan reduces albuminuria in diabetic apoE KO mice.

Volume 73, Issue 11, Pages (June 2008)

Mean Pulmonary Artery Pressure Change Post-Thrombectomy Average pre-procedural mean pulmonary artery pressure (mPAP) in patients with pulmonary hypertension.

(D) Systolic blood pressure (BP) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. . (D) Systolic blood pressure.

Changes in 44-hour interdialytic systolic BP as a function of change in echocardiographic volume parameter. Changes in 44-hour interdialytic systolic BP.

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Role of - Azilsartan - Azilsartan/chlorthalidone

The combined effects of low sodium and the DASH diet according to baseline blood pressure. The combined effects of low sodium and the DASH diet according.

Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.

Presentation transcript:

VAL-MARC: Change in systolic blood pressure (SBP) at 6 weeks by treatment assignment End point Valsartan Valsartan+HCTZ p Change in SBP at 6 weeks (primary BP end point) (mm Hg) -18 -25 <0.001 Proportion of patients reaching goal (%) 32 48 <0.0001 Ridker PM et al. Hypertension 2006; Available at: http://hyper.ahajournals.org.

VAL-MARC: Median change in hs-CRP at 6 weeks by treatment assignment Measure Valsartan Valsartan + HCTZ p hs-CRP median (mg/dL) Baseline 2.11 2.07 6 weeks 1.98 2.15 Median change (mg/dL) -0.12 +0.05 <0.001 Median change (%) -8.9 +4.4 Ridker PM et al. Hypertension 2006; Available at: http://hyper.ahajournals.org.